We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study of BLZ-100 in Pediatric Subjects With CNS Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02462629
Recruitment Status : Completed
First Posted : June 4, 2015
Last Update Posted : November 26, 2018
Information provided by (Responsible Party):
Blaze Bioscience Inc.

Brief Summary:
Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor site, resulting in incomplete removal of the tumor and reduced patient survival. In some sites, such as the brain, it is critical to avoid damage to normal tissue around the tumor to prevent adverse effects of surgery on function. The investigators hypothesize that BLZ-100 will improve surgical outcomes by allowing surgeons to visualize the edges of the tumor and small groups of cancer cells that have spread to other sites in real-time as they operate. This is a safety study to assess the safety of BLZ-100 in pediatric patients with central nervous system tumors.

Condition or disease Intervention/treatment Phase
Central Nervous System Tumors Drug: BLZ-100 Phase 1

Detailed Description:

Subjects who provide voluntary written informed consent, or have it provided by their legally acceptable representative, will be screened for eligibility. Subjects meeting all of the inclusion and none of the exclusion criteria will be eligible to participate.

Subjects will be required to arrive at the hospital for dosing at least 1 hour before the planned surgical excision. Following dosing, subjects will be monitored for safety and surgical excision will occur at least 1 hour after study product administration.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Phase 1 Dose-escalation and Expansion Study of BLZ-100 in Pediatric Subjects With Primary Central Nervous System Tumors
Actual Study Start Date : June 2015
Actual Primary Completion Date : July 2018
Actual Study Completion Date : August 2018

Arm Intervention/treatment
Experimental: BLZ-100 Drug: BLZ-100
Other Names:
  • Tumor Paint
  • tozuleristide

Primary Outcome Measures :
  1. Number of participants with adverse events [ Time Frame: Seven days after study drug administration ]
    Safety will be assessed by physical examination and measurement of vital signs and laboratory safety parameters.

  2. Change in concentration of BLZ-100 in the blood [ Time Frame: Prior to dosing and at 10 minutes, 30 minutes, and 60 minutes post BLZ-100 administration ]
    BLZ-100 levels in blood will be analyzed by chemical means and these data will be used to calculate pharmacokinetic parameters.

Secondary Outcome Measures :
  1. Fluorescence signal in excised central nervous system tumors [ Time Frame: At least 1 hour post-dose ]
    Fluorescence signal in sections of excised tumor and adjacent normal tissue will be measured using an infrared imaging system.

  2. Extent of resection (expansion cohort only) [ Time Frame: At completion of surgery for surgeon assessment and up to 1 week after surgery for MRI assessment ]
    For subjects enrolled in the expansion cohort, an extent of resection assessment will be made by the surgeon and confirmed by post-operative MRI according to standard of care procedures.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Month to 30 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age: >1 month and <30 years at time of enrollment
  2. Diagnosis: Must have MRI documenting a measurable lesion w/in central nervous system consistent with primary central nervous system tumor, for which maximal safe surgical resection is indicated
  3. Timing of surgery: Must be anticipated to take place at least 1 hour after BLZ-100 administration
  4. Prior therapy: Must have recovered from acute toxic effects of prior anti-cancer therapy (durations relative to date of enrollment):

    • Radiation therapy: may not have had radiation therapy to area of tumor planned to be resected w/in 28 days
    • Chemotherapy: ≥14 days from any myelosuppressive chemotherapy and abs neutrophil ct ≥1000/mm3 , 42 days if prior nitrosurea
    • Biologic: ≥7 days from anti-neoplastic biologic agent
    • Immunotherapy: ≥42 days after completion of immunotherapy
    • Monoclonal antibody: ≥3 half-lives of antibody since last admin.
  5. Organ function requirements:

    • Adequate renal function defined as:

      • serum creatinine w/in normal limits or
      • calculated creatinine clearance > 100 mL/min/1.73 m2
    • Adequate liver function defined as:

      • bilirubin <2x upper limit of normal for age
      • alanine aminotransferase <3x upper limit of normal for age (<135 U/mL)
      • serum albumin >2g/dL
    • Adequate coagulation defined as:

      • no evidence of active/clinically significant bleeding. May be evidence of punctate hemorrhage w/in tumor as long as not considered clinically significant to warrant urgent surgical evacuation
      • internal normalized ratio and partial thromboplastin time <1.5x upper limit of normal
  6. Informed Consent: Written informed consent must be obtained from subject or parent/legal guardian prior to enrollment. Assent, when appropriate, will be obtained according to institutional guidelines

Exclusion Criteria:

  1. Pregnancy and contraception: Subjects who are pregnant, breast-feeding or planning to conceive within 30 days are not eligible
  2. Concomitant medications:

    • Corticosteroids: no restrictions
    • Investigational drugs: must not be receiving other investigational (from other studies) drugs at time of enrollment and must not be planning to take other investigational drugs during DLT period
    • Anti-cancer agents: must not be receiving other anti-cancer agents at time of enrollment and must not be planning to take other anti-cancer agents during DLT period
    • Anticoagulation: if currently receiving therapeutic anticoagulation with heparin, low-molecular weight heparin, or Coumadin, not eligible
    • Anti-platelet agents: if currently receiving aspirin, ibuprofen or other non-steroidal anti-inflammatory or anti-platelet agents, not eligible
    • Photosensitizing drugs, medications which might generate fluorescence or according to label, might generate photochemical reaction. These include hematoporphyrin derivatives and purified fractions; Photofrin®; and precursors of protoporphyrin IX (5-Aminolevulinic acid) used in Gliolan or Hexvix
    • Subjects must not have received BLZ-100 within 30 days prior to re-treatment
  3. Infection: Subjects with uncontrolled infection not eligible
  4. Bleeding and Thrombosis:

    • If active bleeding requiring acute surgical intervention, not eligible
    • Subjects with stroke, arterial or venous thrombosis within 6 months not eligible
    • Subjects requiring anticoagulation not eligible
  5. Acuity of surgical needs: Subjects with acute neurologic compromise, symptoms of impending cerebral herniation, or other condition(s) necessitating urgent or emergent neurosurgical intervention to be planned within 2 hours not eligible. NOTE: If subject is enrolled on study, receives study medication and subsequently condition worsens such that urgent surgical intervention is felt to be in best interest of subject, best interest of subject should always take precedence over timing between study medication and surgery
  6. Required observations: Subjects who in opinion of investigator may not be able to comply with required safety and monitoring requirements are not eligible

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02462629

Layout table for location information
United States, Washington
Seattle Children's
Seattle, Washington, United States, 98105
Sponsors and Collaborators
Blaze Bioscience Inc.
Layout table for investigator information
Principal Investigator: Sarah Leary, MD, MS Seattle Children's
Layout table for additonal information
Responsible Party: Blaze Bioscience Inc.
ClinicalTrials.gov Identifier: NCT02462629    
Other Study ID Numbers: BB-004
First Posted: June 4, 2015    Key Record Dates
Last Update Posted: November 26, 2018
Last Verified: November 2018
Keywords provided by Blaze Bioscience Inc.:
central nervous system tumor
Tumor Paint
brain cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms by Site
Nervous System Diseases